Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TNF Pharmaceuticals, Inc. (TNFA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: TNFA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.74% | Avg. Invested days 10 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.94M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.42 | 52 Weeks Range 0.12 - 2.16 | Updated Date 06/28/2025 |
52 Weeks Range 0.12 - 2.16 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.37 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.36% | Return on Equity (TTM) -121.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1362948 | Price to Sales(TTM) - |
Enterprise Value 1362948 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 14184100 | Shares Floating 14166074 |
Shares Outstanding 14184100 | Shares Floating 14166074 | ||
Percent Insiders 0.11 | Percent Institutions 3.43 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TNF Pharmaceuticals, Inc.
Company Overview
History and Background
It is difficult to provide a complete overview of TNF Pharmaceuticals, Inc. without access to specific and up-to-date company information. As an AI model, I do not have direct access to real-time databases or proprietary information. The TNF Pharmaceuticals Inc. website has been offline for sometime. Therefore, the following is based on publicly available information. TNF Pharmaceuticals, Inc. seems to be a development-stage pharmaceutical company. Information about its founding year and specific milestones is limited. The company has been focused on developing therapies for ophthalmic diseases, including dry eye disease, glaucoma, and age-related macular degeneration.
Core Business Areas
- Pharmaceutical Development: Focused on developing and commercializing novel therapies for ophthalmic diseases.
- Drug Delivery Systems: Developing innovative drug delivery technologies to improve the efficacy and patient compliance of ophthalmic treatments.
Leadership and Structure
Information about the specific leadership team and organizational structure of TNF Pharmaceuticals, Inc. is not readily available. Typically, a company of this nature would have a CEO, CSO, and CFO, with various departments for research and development, clinical trials, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- TNP-201 (Dry Eye Disease): A novel formulation being developed for the treatment of dry eye disease. Specific market share data is unavailable. Competitors include AbbVie (Restasis and Xiidra), Novartis (Cyclosporine generics), and others developing novel dry eye therapies.
- TNP-150 (Glaucoma): A product candidate aimed at lowering intraocular pressure in glaucoma patients. Specific market share data is unavailable. Competitors include Allergan (now AbbVie), Novartis, and numerous generic manufacturers of prostaglandin analogs and other glaucoma medications.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the ophthalmology segment, is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market is driven by an aging population, increasing prevalence of eye diseases, and advancements in treatment options.
Positioning
TNF Pharmaceuticals, Inc. aims to position itself as an innovator in the ophthalmic space, focusing on developing novel therapies and drug delivery systems. Success depends on clinical trial outcomes, regulatory approvals, and commercialization strategies.
Total Addressable Market (TAM)
The global ophthalmic pharmaceutical market is estimated to be in the tens of billions of US dollars, and is expected to grow in the coming years. TNF Pharmaceuticals, Inc.'s positioning with respect to this TAM depends on the success of its product candidates and its ability to capture market share.
Upturn SWOT Analysis
Strengths
- Novel drug candidates in development
- Potential for innovative drug delivery systems
- Focus on high-growth ophthalmic market
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Lack of established commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- FDA approval and commercialization of product candidates
- Expansion into new ophthalmic indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expiration
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- PFE
Competitive Landscape
TNF Pharmaceuticals, Inc. faces significant challenges in competing with larger, more established pharmaceutical companies. Its success depends on the novelty and efficacy of its product candidates and its ability to secure funding and partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not publicly available.
Future Projections: Future projections are highly speculative due to the company's development stage and the uncertainty of clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent strategic initiatives for TNF Pharmaceuticals, Inc. cannot be highlighted without additional information. Potential initiatives would include clinical trial progress, partnership agreements, and regulatory submissions.
Summary
TNF Pharmaceuticals, Inc. is a development-stage pharmaceutical company focused on ophthalmic diseases. The company's strength lies in its novel drug candidates, but it faces challenges due to limited financial resources and dependence on clinical trial success. Potential opportunities include partnerships and regulatory approvals. It needs to lookout for competition from established pharmaceutical companies and potential clinical trial failures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website (offline - last archived version)
- SEC Filings (limited availability)
- Industry Reports
- News Articles
Disclaimers:
This analysis is based on limited publicly available information. The pharmaceutical industry is highly dynamic and subject to change. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TNF Pharmaceuticals, Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2014-01-23 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://tnfpharma.com |
Full time employees 2 | Website https://tnfpharma.com | ||
TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.